Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Label Study: Safety and Efficacy of a New Ablation Catheter RFA (Radiofrequency Under EUS) Developed by TAEWOONG Company for the Treatment of Pancreatic Premalignant and Early Malignant Cyctic Lesions.

NCT03417843 is registered in ClinicalTrials.gov with HaEmek Medical Center, Israel as lead sponsor.

NCT NCT03417843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03417843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Label Study: Safety and Efficacy of a New Ablation Catheter RFA (Radiofrequency Under EUS) Developed by TAEWOONG Company for the Treatment of Pancreatic Premalignant and Early Malignant Cyctic Lesions.
Lead sponsor
HaEmek Medical Center, Israel
Phase
Not applicable
Overall status
Unknown status
Start date
February 28, 2018
Completion date
February 28, 2021
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic cancer stage, pancreatic cyst, pancreatic neuroendocrine tumor